Available Technologies
# of Displayed Technologies: 10 / 19
Applied Category Filter (Click To Remove): Therapeutics
Breakthrough In Delivery: Expanding Access to Intracellular Targets for Next-Generation Therapies
TS-072004 — Empower your pipeline with a versatile platform for efficient, customizable biomolecule transport.
Overview
Intracellular delivery remains a persistent challenge in drug delivery, gene editing, and biotechnology. Pharmaceutical and biotech companies lose valuable opportunities when promising drugs and biologics cannot reach their intended targets inside cells, limiting product effectiveness and m…
- College: College of Arts & Sciences
- Inventors: Bong, Dennis
- Licensing Officer: Panic, Ana
Revolutionizing Corneal Repair: Advanced MG53-Based Treatment for Enhanced Ocular Health
TS-066878 — New and more effective treatments for corneal injuries.
Current treatments for corneal injuries often have side effects that can compromise vision, highlighting the need for a new method that enhances ocular tissue repair without such drawbacks.
The Need
Injuries to the cornea can lead to severe pain, infection, and vision loss due to scarring and abno…
- College: College of Optometry
- Inventors: Chandler, Heather; Ma, Jianjie; Tan, Tao; Zhu, Hua
- Licensing Officer: Schultz, Teri
Small Molecule USP30 Inhibitors for the Treatment and Prevention of Cardiomyopathy
TS-066773 — The Need
Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…
- College: College of Medicine (COM)
- Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
- Licensing Officer: Willson, Christopher
Innovative Small Molecule Inhibitors for Effective Treatment and Prevention of Coronavirus Infections
TS-066750 —
The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health and economies. Despite vaccine efforts, issues such as vaccine hesitancy, delays in distribution, and emerging variants have highlighted the need for effective therapeutic interventions. These i…
- College: College of Veterinary Medicine
- Inventors: Sharma, Amit; Li, Pui-Kai "Tom"; Xing, Enming
- Licensing Officer: Willson, Christopher
Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males.
The Need
Despite the crucial role of androgen receptors (AR) in HCC progress…
- College: College of Pharmacy
- Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
- Licensing Officer: Willson, Christopher
Immune Based Neuroprotective & Neuroregenerative Therapies
TS-062688 — Conditioned neutrophils and cell therapy vectors for nerve regeneration
The Need
Neurological disorders arising from central nervous system (CNS) injuries and diseases pose significant challenges to quality of life. The limited capacity of CNS neurons to regenerate and the lack of effective therapies for conditions like glaucoma, optic nerve injury, and spinal cord inj…
- College: College of Medicine (COM)
- Inventors: Segal, Benjamin; Jerome, Andrew; Liu, Tom; Sas, Andrew
- Licensing Officer: Bhatti, Hamid
Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Pharmacy
- Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
- Licensing Officer: Willson, Christopher
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Bhatti, Hamid
An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Bhatti, Hamid
Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need:
Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
- Licensing Officer: Schworer, Adam
